Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 12/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 2/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.32 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23289300 | 0.91 | TLR8 (0.42) | TLR8TLR7 | |
| SCHEMBL23289650 | 0.87 | TLR8 (0.40) | TLR8TLR7 | |
| SCHEMBL23273948 | 0.86 | TLR8 (0.39) | TLR8TLR7 | |
| SCHEMBL23289381 | 0.84 | TLR8 (0.43) | TLR8TLR7LPAR1LPAR5 | |
| SCHEMBL25963864 | 0.84 | TLR8 (0.41) | TLR8TLR7 | |
| SCHEMBL23289353 | 0.83 | TLR8 (0.41) | TLR8TLR7CA1CA2 | |
| SCHEMBL23289307 | 0.83 | CA1 (0.35) | TLR8CA1CA2ATRL3MBTL1 | |
| SCHEMBL25963224 | 0.83 | TLR8 (0.41) | TLR8TLR7 | |
| SCHEMBL23289339 | 0.82 | TLR8 (0.41) | TLR8TLR7 | |
| SCHEMBL23289375 | 0.82 | TLR8 (0.38) | TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338571-A1 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230257393-A1 | MACROMOLECULE-SUPPORTED THIENOAZEPINE COMPOUNDS, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230257393-A1 | MACROMOLECULE-SUPPORTED THIENOAZEPINE COMPOUNDS, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-08-17 | — | — | US | disclosed |
| US-11654199-B2 | Thienoazepine immunoconjugates, and uses thereof | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-11654199-B2 | Thienoazepine immunoconjugates, and uses thereof | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-20210128744-A1 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2021-05-06 | — | — | US | disclosed |
| WO-2021081407-A1 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2021-04-29 | — | — | WO | disclosed |
| WO-2021081402-A1 | MACROMOLECULE-SUPPORTED THIENOAZEPINE COMPOUNDS, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2021-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338571-A1 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | ICOS, CYP3A5, TPH1 | TLR8 3844/4885TLR7 2077/4885CA1 1483/4885 |
| US-11654199-B2 | Thienoazepine immunoconjugates, and uses thereof | ICOS, CYP3A5, TPH1 | TLR8 3844/4885TLR7 2077/4885CA1 1483/4885 |
| US-20230257393-A1 | MACROMOLECULE-SUPPORTED THIENOAZEPINE COMPOUNDS, AND USES THEREOF | HTR3D, PNMT, HTR3B | TLR8 4164/4885TLR7 4231/4885CA1 2776/4885 |
| US-20210128744-A1 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | ICOS, CYP3A5, TPH1 | TLR8 3844/4885TLR7 2077/4885CA1 1483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.